Fintel reports that on June 5, 2024, Guggenheim initiated coverage of Twist Bioscience (NasdaqGS:TWST) with a Buy recommendation.
Analyst Price Forecast Suggests 15.42% Downside
As of June 2, 2024, the average one-year price target for Twist Bioscience is 44.64. The forecasts range from a low of 31.42 to a high of $57.75. The average price target represents a decrease of 15.42% from its latest reported closing price of 52.78.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Twist Bioscience is 353MM, an increase of 27.17%. The projected annual non-GAAP EPS is -4.34.
What is the Fund Sentiment?
There are 509 funds or institutions reporting positions in Twist Bioscience. This is an increase of 31 owner(s) or 6.49% in the last quarter. Average portfolio weight of all funds dedicated to TWST is 0.22%, an increase of 0.08%. Total shares owned by institutions increased in the last three months by 1.75% to 84,486K shares. 
The put/call ratio of TWST is 0.97, indicating a bullish outlook.
What are Other Shareholders Doing?
ARK Investment Management holds 6,944K shares representing 11.93% ownership of the company. In its prior filing, the firm reported owning 7,213K shares , representing a decrease of 3.88%. The firm increased its portfolio allocation in TWST by 4.80% over the last quarter.
Artisan Partners Limited Partnership holds 4,642K shares representing 7.97% ownership of the company. In its prior filing, the firm reported owning 3,723K shares , representing an increase of 19.78%. The firm increased its portfolio allocation in TWST by 9.01% over the last quarter.
Jpmorgan Chase holds 3,614K shares representing 6.21% ownership of the company. In its prior filing, the firm reported owning 4,616K shares , representing a decrease of 27.73%. The firm decreased its portfolio allocation in TWST by 92.85% over the last quarter.
Nikko Asset Management Americas holds 3,551K shares representing 6.10% ownership of the company. In its prior filing, the firm reported owning 3,583K shares , representing a decrease of 0.90%. The firm decreased its portfolio allocation in TWST by 4.66% over the last quarter.
Sumitomo Mitsui Trust Holdings holds 3,551K shares representing 6.10% ownership of the company. In its prior filing, the firm reported owning 3,583K shares , representing a decrease of 0.90%. The firm decreased its portfolio allocation in TWST by 15.11% over the last quarter.
Twist Bioscience Background Information
(This description is provided by the company.)
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by 'writing' DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
